U.S. patent application number 11/888450 was filed with the patent office on 2008-02-21 for cyclic sulfonamides for inhibition of gamma-secretase.
Invention is credited to Kevin Dinnell, Timothy Harrison, Alan John Nadin, Andrew Pate Owens, Duncan Edward Shaw, Brian John Williams.
Application Number | 20080045515 11/888450 |
Document ID | / |
Family ID | 33420897 |
Filed Date | 2008-02-21 |
United States Patent
Application |
20080045515 |
Kind Code |
A1 |
Dinnell; Kevin ; et
al. |
February 21, 2008 |
Cyclic sulfonamides for inhibition of gamma-secretase
Abstract
Compounds of formula I: ##STR1## inhibit the processing of APP
by gamma-secretase, and hence are useful in the treatment or
prevention of Alzheimer's disease.
Inventors: |
Dinnell; Kevin; (Much
Hadham, GB) ; Harrison; Timothy; (Great Dunmow,
GB) ; Nadin; Alan John; (Sawbridgeworth, GB) ;
Owens; Andrew Pate; (Hungtingdon, GB) ; Shaw; Duncan
Edward; (Bishops Stortford, GB) ; Williams; Brian
John; (Great Dunmow, GB) |
Correspondence
Address: |
MERCK AND CO., INC
P O BOX 2000
RAHWAY
NJ
07065-0907
US
|
Family ID: |
33420897 |
Appl. No.: |
11/888450 |
Filed: |
August 1, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10845833 |
May 14, 2004 |
|
|
|
11888450 |
Aug 1, 2007 |
|
|
|
Current U.S.
Class: |
514/226.5 ;
544/47 |
Current CPC
Class: |
C07D 279/02 20130101;
A61P 25/00 20180101; A61P 25/28 20180101; A61P 43/00 20180101 |
Class at
Publication: |
514/226.5 ;
544/047 |
International
Class: |
A61K 31/54 20060101
A61K031/54; A61P 25/00 20060101 A61P025/00; C07D 279/02 20060101
C07D279/02 |
Foreign Application Data
Date |
Code |
Application Number |
May 16, 2003 |
GB |
0311341.2 |
Nov 20, 2003 |
GB |
0327055.0 |
Claims
1. A compound of formula I: ##STR41## wherein the bonds indicated
by wavy lines are mutually cis with respect to the cyclohexane
ring; R.sup.3 represents H or a hydrocarbon group of up to 10
carbon atoms, optionally substituted with CF.sub.3, CHF.sub.2,
halogen, CN, OR.sup.5, COR.sup.5, CO.sub.2R.sup.5, OCOR.sup.6,
N(R.sup.5).sub.2, CON(R.sup.5).sub.2 or NR.sup.5COR.sup.6; R.sup.5
represents H or C.sub.1-4alkyl; R.sup.6 represents C.sub.1-4alkyl;
and Ar.sup.1 and Ar.sup.2 independently represent phenyl or
heteroaryl, either of which bears 0-3 substituents independently
selected from halogen, CN, NO.sub.2, CF.sub.3, CHF.sub.2, OH,
OCF.sub.3, CHO, CH.dbd.NOH, C.sub.1-4alkoxy,
C.sub.1-4alkoxycarbonyl, C.sub.2-6acyl, C.sub.2-6alkenyl and
C.sub.1-4alkyl which optionally bears a substituent selected from
halogen, CN, NO.sub.2, CF.sub.3, OH and C.sub.1-4alkoxy; or a
pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 wherein Ar.sup.1 is selected
from 6-(trifluoromethyl)-3-pyridyl and phenyl which is optionally
substituted in the 4-position with halogen, CN, vinyl, allyl,
acetyl, methyl or mono-, di- or trifluoromethyl; and Ar.sup.2 is
selected from phenyl groups bearing halogen substituents in the 2-
and 5-positions, the 2- and 6-positions, or in the 2-, 3- and
6-positions.
3. A compound according to claim 2 wherein Ar.sup.1 is
4-chlorophenyl or 4-trifluoromethylphenyl and Ar.sup.2 is
2,5-difluorophenyl.
4. A compound according to any previous claim wherein R.sup.3
represents H or a non-aromatic hydrocarbon group of up to 6 carbon
atoms which is unsubstituted.
5. A compound according to claim 4 wherein R.sup.3 represents H,
methyl, ethyl, n-propyl, isopropyl or allyl.
6. A compound according to claim 5 selected from
(4aRS,6RS,8aSR)-6-(2,5-difluorophenyl)-6-{[4-(trifluoromethyl)phenyl]sulf-
onyl}octahydro-1H-2,1-benzothiazine 2,2-dioxide;
(3S,4aR,6R,8aS)-6-(2,5-difluorophenyl)-3-ethyl-6-{[4-(trifluoromethyl)phe-
nyl]sulfonyl}octahydro-1H-2,1-benzothiazine 2,2-dioxide;
(3R,4aR,6R,8aS)-6-(2,5-difluorophenyl)-3-ethyl-6-{[4-(trifluoromethyl)phe-
nyl]sulfonyl}octahydro-1H-2,1-benzothiazine 2,2-dioxide;
(3RS,4aRS,6RS,8aSR)-6-(2,5-difluorophenyl)-3-isopropyl-6-{[4-(trifluorome-
thyl)phenyl]sulfonyl}octahydro-1H-2,1-benzothiazine 2,2-dioxide;
(3SR,4aRS,6RS,8aSR)-6-(2,5-difluorophenyl)-3-isopropyl-6-{[4-(trifluorome-
thyl)phenyl]sulfonyl}octahydro-1H-2,1-benzothiazine 2,2-dioxide;
and
(3S,4aR,6R,8aS)-6-[(4-chlorophenyl)sulfonyl]-6-(2,5-difluorophenyl)-3-eth-
yloctahydro-1H-2,1-benzothiazine 2,2-dioxide; and the
pharmaceutically acceptable salts thereof.
7. A pharmaceutical composition comprising a compound according to
any previous claim and a pharmaceutically acceptable carrier.
8. A compound according to any of claims 1-6 for use in a method of
treatment of the human body.
9. Use of a compound according to any of claims 1-6 for the
manufacture of a medicament for treating or preventing Alzheimer's
disease.
10. A process for preparing a compound of formula I as defined in
claim 1 comprising the steps of: (a) cyclising a compound of
formula (2): ##STR42## by treatment with strong base in an aprotic
solvent to form a compound of formula (1): ##STR43## (b) optionally
alkylating the compound of formula (1) with R.sup.3a-L; and (c)
removing the N-protecting group; where Prt is a protecting group, L
is a leaving group, R.sup.3a is R.sup.3 that is other than H,
R.sup.a is C.sub.1-6alkyl which optionally bears up to 3 halogen
substituents, or phenyl which optionally bears up to 3 substituents
selected from halogen and C.sub.1-4alkyl, and Ar.sup.1, Ar.sup.2
and R.sup.3 are as defined in claim 1.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation under 35 U.S.C. .sctn.120
of U.S. patent application Ser. No. 10/845,833, filed May 14, 2004,
which claimed priority under 35 U.S.C. .sctn.119(e) of Great
Britain application no. 0311341.2, filed May 16, 2003, and Great
Britain application no. 0327055.0, filed Nov. 20, 2003.
[0002] The present invention relates to a novel class of compounds,
their salts, pharmaceutical compositions comprising them, processes
for making them and their use in therapy of the human body. In
particular, the invention relates to novel cyclohexyl sulfones
comprising an additional fused ring cyclic sulfonamide group. The
compounds inhibit the processing of APP by .gamma.-secretase so as
to suppress or attenuate the secretion of .beta.-amyloid, and hence
are useful in the treatment or prevention of Alzheimer's
disease.
[0003] Alzheimer's disease (AD) is the most prevalent form of
dementia. Although primarily a disease of the elderly, affecting up
to 10% of the population over the age of 65, AD also affects
significant numbers of younger patients with a genetic
predisposition. It is a neurodegenerative disorder, clinically
characterized by progressive loss of memory and cognitive function,
and pathologically characterized by the deposition of extracellular
proteinaceous plaques in the cortical and associative brain regions
of sufferers. These plaques mainly comprise fibrillar aggregates of
.beta.-amyloid peptide (A.beta.). The role of secretases, including
the putative .gamma.-secretase, in the processing of amyloid
precursor protein (APP) to form A.beta. is well documented in the
literature and is reviewed, for example, in WO 01/70677.
[0004] There is a growing number of reports in the literature of
compounds with inhibitory activity towards .gamma.-secretase, as
measured in cell-based assays (see, for example, WO 01/70677 and
references therein). Many of the relevant compounds are peptides or
peptide derivatives.
[0005] WO 00/50391 discloses a broad class of sulfonamides as
modulators of the production of .beta.-amyloid, but neither
discloses nor suggests the compounds of the present invention. WO
01/70677, WO 02/36555 and WO 02/081435 disclose, respectively,
classes of sulfonamides, sulfamides and cyclohexyl sulfones which
inhibit .gamma.-secretase, but neither disclose nor suggest the
compounds of the present invention.
[0006] The present invention provides a novel class of cyclohexyl
sulfones comprising an additional fused ring which contains a
sulfonamide group. The compounds inhibit the processing of APP by
the putative .gamma.-secretase so as to suppress or attenuate the
production of A.beta., and hence are useful in the treatment or
prevention of AD.
[0007] According to the invention there is provided a compound of
formula I: ##STR2##
[0008] wherein the bonds indicated by wavy lines are mutually cis
with respect to the cyclohexane ring;
[0009] R.sup.3 represents H or a hydrocarbon group of up to 10
carbon atoms, optionally substituted with CF.sub.3, CHF.sub.2,
halogen, CN, OR.sup.5, COR.sup.5, CO.sub.2R.sup.5, OCOR.sup.6,
N(R.sup.5).sub.2, CON(R.sup.5).sub.2 or NR.sup.5COR.sup.6;
[0010] R.sup.5 represents H or C.sub.1-4alkyl;
[0011] R.sup.6 represents C.sub.1-4alkyl; and
[0012] Ar.sup.1 and Ar.sup.2 independently represent phenyl or
heteroaryl, either of which bears 0-3 substituents independently
selected from halogen, CN, NO.sub.2, CF.sub.3, CHF.sub.2, OH,
OCF.sub.3, CHO, CH.dbd.NOH, C.sub.1-4alkoxy,
C.sub.1-4alkoxycarbonyl, C.sub.2-6acyl, C.sub.2-6alkenyl and
C.sub.1-4alkyl which optionally bears a substituent selected from
halogen, CN, NO.sub.2, CF.sub.3, OH and C.sub.1-4alkoxy;
[0013] or a pharmaceutically acceptable salt thereof.
[0014] In formula I and other formulae presented herein a
convention is used whereby wavy lines denote bonds which are
mutually cis with respect to the cyclohexane ring. Such bonds
either all project upwards from the ring or all project downwards
from the ring. Sigma bonds attached to the cyclohexane ring and
represented by a solid line necessarily have the opposite
orientation to that of the bonds represented by wavy lines.
[0015] The compounds of formula I exist in two enantiomeric forms,
depending on whether the bonds indicated by wavy lines project
upwards or downwards, corresponding to formulae IA and IB: ##STR3##
where R.sup.3, Ar.sup.1 and Ar.sup.2 have the same meanings as
before. It is to be understood that any compound in accordance with
the invention may exist in either of the homochiral forms IA and
IB, or as a mixture of the two in any proportion.
[0016] In addition to the isomerism described above, the compounds
according to the invention may comprise one or more asymmetric
centres, and accordingly may exist as enantiomers. Where the
compounds according to the invention possess two or more asymmetric
centres, they may additionally exist as diastereoisomers. It is to
be understood that all such isomers and mixtures thereof in any
proportion are encompassed within the scope of the present
invention.
[0017] Where a variable occurs more than once in formula I, the
individual occurrences are independent of each other, unless
otherwise indicated. As used herein, the expression "hydrocarbon
group" refers to groups consisting solely of carbon and hydrogen
atoms. Such groups may comprise linear, branched or cyclic
structures, singly or in any combination consistent with the
indicated maximum number of carbon atoms, and may be saturated or
unsaturated, including aromatic when the indicated maximum number
of carbon atoms so permits.
[0018] As used herein, the expression "C.sub.1-x-alkyl" where x is
an integer greater than 1 refers to straight-chained and branched
alkyl groups wherein the number of constituent carbon atoms is in
the range 1 to x. Particular alkyl groups are methyl, ethyl,
n-propyl, isopropyl and t-butyl. Derived expressions such as
"C.sub.2-6alkenyl", "hydroxyC.sub.1-6alkyl",
"heteroarylC.sub.1-6alkyl", "C.sub.2-6alkynyl" and
"C.sub.1-6alkoxy" are to be construed in an analogous manner. Most
suitably, the number of carbon atoms in such groups is not more
than 6.
[0019] The expression "C.sub.2-6acyl" as used herein refers to
C.sub.1-5alkylcarbonyl groups in which the alkyl portion may be
straight chain, branched or cyclic, and may be halogenated.
Examples include acetyl, propionyl and trifluoroacetyl.
[0020] The expression "heteroaryl" as used herein means a
monocyclic system of 5 or 6 ring atoms, or fused bicyclic system of
up to 10 ring atoms, selected from C, N, O and S, wherein at least
one of the constituent rings is aromatic and comprises at least one
ring atom which is other than carbon. Monocyclic systems of 5 or 6
members are preferred. Examples of heteroaryl groups include
pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, furyl,
thienyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,
imidazolyl, oxadiazolyl, triazolyl and thiadiazolyl groups and
benzo-fused analogues thereof. Further examples of heteroaryl
groups include tetrazole, 1,2,4-triazine and 1,3,5-triazine.
Pyridine rings may be in the N-oxide form.
[0021] Where a phenyl group or heteroaryl group bears more than one
substituent, preferably not more than one of said substituents is
other than halogen or alkyl. Where an alkyl group bears more than
one substituent, preferably not more than one of said substituents
is other than halogen.
[0022] The term "halogen" as used herein includes fluorine,
chlorine, bromine and iodine, of which fluorine and chlorine are
preferred.
[0023] For use in medicine, the compounds of formula I may
advantageously be in the form of pharmaceutically acceptable salts.
Other salts may, however, be useful in the preparation of the
compounds of formula I or of their pharmaceutically acceptable
salts. Suitable pharmaceutically acceptable salts of the compounds
of this invention include acid addition salts which may, for
example, be formed by mixing a solution of the compound according
to the invention with a solution of a pharmaceutically acceptable
acid such as hydrochloric acid, sulfuric acid, benzenesulfonic
acid, methanesulfonic acid, fumaric acid, maleic acid, succinic
acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric
acid, carbonic acid or phosphoric acid. Alternatively, where the
compound of the invention carries an acidic moiety, a
pharmaceutically acceptable salt may be formed by neutralisation of
said acidic moiety with a suitable base. Examples of
pharmaceutically acceptable salts thus formed include alkali metal
salts such as sodium or potassium salts; ammonium salts; alkaline
earth metal salts such as calcium or magnesium salts; and salts
formed with suitable organic bases, such as amine salts (including
pyridinium salts) and quaternary ammonium salts.
[0024] In the compounds of formula I, Ar.sup.1 and Ar.sup.2
independently represent optionally substituted phenyl or
heteroaryl. Ar.sup.1 is preferably selected from optionally
substituted phenyl and optionally substituted 6-membered
heteroaryl. Preferred 6-membered heteroaryl embodiments of Ar.sup.1
include optionally substituted pyridyl, in particular optionally
substituted 3-pyridyl. Ar.sup.1 is preferably selected from
6-(trifluoromethyl)-3-pyridyl and phenyl which is optionally
substituted in the 4-position with halogen, CN, vinyl, allyl,
acetyl, methyl or mono-, di- or trifluoromethyl. In one preferred
embodiment of the invention Ar.sup.1 represents 4-chlorophenyl. In
another preferred embodiment Ar.sup.1 represents
4-trifluoromethylphenyl. In another preferred embodiment Ar.sup.1
represents 6-(trifluoromethyl)-3-pyridyl.
[0025] Ar.sup.2 preferably represents optionally substituted
phenyl, in particular phenyl bearing 2 or 3 substituents selected
from halogen, CN, CF.sub.3 and optionally-substituted alkyl.
Ar.sup.2 is typically selected from phenyl groups bearing halogen
substituents (preferably fluorine) in the 2- and 5-positions, the
2- and 6-positions or in the 2-, 3- and 6-positions, or from phenyl
groups bearing a fluorine substituent in the 2-position and
halogen, CN, methyl or hydroxymethyl in the 5-position. In a
preferred embodiment of the invention, Ar.sup.2 represents
2,5-difluorophenyl, 2,6-difluorophenyl or
2,3,6-trifluorophenyl.
[0026] In a particular embodiment, Ar.sup.1 is 4-chlorophenyl or
4-trifluoromethylphenyl and Ar.sup.2 is 2,5-difluorophenyl.
[0027] R.sup.3 represents H or a hydrocarbon group of up to 10
carbon atoms, optionally substituted as defined previously.
Hydrocarbon groups represented by R.sup.3 are preferably
non-aromatic and unsubstituted, and preferably comprise up to 6
carbon atoms. Typical examples include alkyl groups (such as
methyl, ethyl, n-propyl, isopropyl and n-butyl) and alkenyl groups
(such as allyl).
[0028] Preferred compounds of the invention include those in which
Ar.sup.1 represents 4-chlorophenyl or 4-trifluoromethylphenyl,
Ar.sup.2 represents 2,5-difluorophenyl, and R.sup.3 represents H,
methyl, ethyl, n-propyl, isopropyl or allyl, and pharmaceutically
acceptable salts thereof.
[0029] Specific examples of compounds in accordance with the
invention include: [0030]
(4aRS,6RS,8aSR)-6-(2,5-difluorophenyl)-6-{[4-(trifluoromethyl)phenyl]sulf-
onyl}octahydro-1H-2,1-benzothiazine 2,2-dioxide; [0031]
(3S,4aR,6R,8aS)-6-(2,5-difluorophenyl)-3-ethyl-6-{[4-(trifluoromethyl)phe-
nyl]sulfonyl}octahydro-1H-2,1-benzothiazine 2,2-dioxide; [0032]
(3R,4aR,6R,8aS)-6-(2,5-difluorophenyl)-3-ethyl-6-{[4-(trifluoromethyl)phe-
nyl]sulfonyl}octahydro-1H-2,1-benzothiazine 2,2-dioxide; [0033]
(3RS,4aRS,6RS,8aSR)-6-(2,5-difluorophenyl)-3-isopropyl-6-{[4-(trifluorome-
thyl)phenyl]sulfonyl}octahydro-1H-2,1-benzothiazine 2,2-dioxide;
[0034]
(3SR,4aRS,6RS,8aSR)-6-(2,5-difluorophenyl)-3-isopropyl-6-{[4-(trifluorome-
thyl)phenyl]sulfonyl}octahydro-1H-2,1-benzothiazine 2,2-dioxide;
and [0035]
(3S,4aR,6R,8aS)-6-[(4-chlorophenyl)sulfonyl]-6-(2,5-difluoropheny-
l)-3-ethyloctahydro-1H-2,1-benzothiazine 2,2-dioxide; and the
pharmaceutically acceptable salts thereof.
[0036] The compounds of the present invention have an activity as
inhibitors of .gamma. secretase.
[0037] The invention also provides pharmaceutical compositions
comprising one or more compounds of this invention and a
pharmaceutically acceptable carrier. Preferably these compositions
are in unit dosage forms such as tablets, pills, capsules, powders,
granules, sterile parenteral solutions or suspensions, metered
aerosol or liquid sprays, drops, ampoules, transdermal patches,
auto-injector devices or suppositories; for oral, parenteral,
intranasal, sublingual or rectal administration, or for
administration by inhalation or insufflation. The principal active
ingredient typically is mixed with a pharmaceutical carrier, e.g.
conventional tableting ingredients such as corn starch, lactose,
sucrose, sorbitol, talc, stearic acid, magnesium stearate and
dicalcium phosphate, or gums, dispersing agents, suspending agents
or surfactants such as sorbitan monooleate and polyethylene glycol,
and other pharmaceutical diluents, e.g. water, to form a
homogeneous preformulation composition containing a compound of the
present invention, or a pharmaceutically acceptable salt thereof.
When referring to these preformulation compositions as homogeneous,
it is meant that the active ingredient is dispersed evenly
throughout the composition so that the composition may be readily
subdivided into equally effective unit dosage forms such as
tablets, pills and capsules. This preformulation composition is
then subdivided into unit dosage forms of the type described above
containing from 0.1 to about 500 mg of the active ingredient of the
present invention. Typical unit dosage forms contain from 1 to 100
mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active
ingredient. Tablets or pills of the novel composition can be coated
or otherwise compounded to provide a dosage form affording the
advantage of prolonged action. For example, the tablet or pill can
comprise an inner dosage and an outer dosage component, the latter
being in the form of an envelope over the former. The two
components can be separated by an enteric layer which serves to
resist disintegration in the stomach and permits the inner
component to pass intact into the duodenum or to be delayed in
release. A variety of materials can be used for such enteric layers
or coatings, such materials including a number of polymeric acids
and mixtures of polymeric acids with such materials as shellac,
cetyl alcohol and cellulose acetate.
[0038] The liquid forms in which the novel compositions of the
present invention may be incorporated for administration orally or
by injection include aqueous solutions, liquid- or gel-filled
capsules, suitably flavored syrups, aqueous or oil suspensions, and
flavored emulsions with edible oils such as cottonseed oil, sesame
oil or coconut oil, as well as elixirs and similar pharmaceutical
vehicles. Suitable dispersing or suspending agents for aqueous
suspensions include synthetic and natural gums such as tragacanth,
acacia, alginate, dextran, sodium carboxymethylcellulose,
methylcellulose, poly(ethylene glycol), poly(vinylpyrrolidone) or
gelatin.
[0039] The present invention also provides a compound of formula I
or a pharmaceutically acceptable salt thereof for use in a method
of treatment of the human body. Preferably the treatment is for a
condition associated with the deposition of .beta.-amyloid.
Preferably the condition is a neurological disease having
associated .beta.-amyloid deposition such as Alzheimer's
disease.
[0040] The present invention further provides the use of a compound
of formula I or a pharmaceutically acceptable salt thereof in the
manufacture of a medicament for treating or preventing Alzheimer's
disease.
[0041] Also disclosed is a method of treatment of a subject
suffering from or prone to Alzheimer's disease which comprises
administering to that subject an effective amount of a compound
according to the present invention or a pharmaceutically acceptable
salt thereof.
[0042] For treating or preventing Alzheimer's disease, a suitable
dosage level is about 0.01 to 250 mg/kg per day, preferably about
0.05 to 100 mg/kg per day, more preferably about 0.1 to 50 mg/kg of
body weight per day, and for the most preferred compounds, about
0.1 to 20 mg/kg of body weight per day. The compounds may be
administered on a regimen of 1 to 4 times per day. In some cases,
however, a dosage outside these limits may be used.
[0043] A preferred route to compounds of formula I in which R.sup.3
is other than H comprises alkylation of compounds (1) with
R.sup.3a-L, followed by cleavage of the N-protecting group:
##STR4## where R.sup.3a is R.sup.3 that is other than H, L is a
leaving group such as halide (especially bromide or iodide),
mesylate, tosylate or triflate, Prt is a protecting group such as
p-methoxybenzyl, and Ar.sup.1 and Ar.sup.2 have the same meanings
as before. The alkylation takes place in an aprotic solvent (such
as THF) in the presence of strong base (such as lithium
bis(trimethylsilyl)amide) at reduced temperature (e.g. -78.degree.
C.). When Prt is p-methoxybenzyl, cleavage may be effected by
treatment with acid, e.g. trifluoroacetic acid at ambient
temperature in an inert solvent such as dichloromethane.
[0044] A preferred route to compounds (1) involves cyclisation of
sulfonamides (2): ##STR5## where Ar.sup.1, Ar.sup.2 and Prt have
the same meanings as before, and R.sup.a represents C.sub.1-6alkyl
which optionally bears up to 3 halogen substituents (such as F or
Cl), or phenyl which optionally bears up to 3 substituents selected
from halogen and C.sub.1-4alkyl. Examples of groups represented by
R.sup.a include methyl, CF.sub.3, phenyl, and p-tolyl, of which
methyl is preferred. The cyclisation may be carried out by
treatment with strong base such as sodium hydride in an aprotic
solvent such as DMF at moderately elevated temperature (e.g. about
75.degree. C.).
[0045] Compounds (2) are obtainable by reaction of sulfonyl
chlorides (3) with PrtNH.sub.2: ##STR6## where R.sup.a, Ar.sup.1,
Ar.sup.2 and Prt have the same meanings as before. The reaction may
be carried out in an inert solvent such as dichloromethane at about
0.degree. C. using an excess of the amine.
[0046] Sulfonyl chlorides (3) are obtainable by reaction of
sulfonates (4) with thiourea and treatment of the resulting adducts
with chlorine: ##STR7## where R.sup.a, Ar.sup.1 and Ar.sup.2 have
the same meanings as before. The reaction with thiourea may be
carried out in refluxing ethanol, and the resulting adduct may be
treated with gaseous chlorine in aqueous acetic acid solution.
[0047] Sulfonates (4) are obtainable by treatment of diols (5) with
R.sup.aSO.sub.2Cl or (R.sup.aSO.sub.2).sub.2O: ##STR8## where
R.sup.a, Ar.sup.1 and Ar.sup.2 have the same meanings as before.
The reaction is conveniently carried out in dichloromethane at
about -10.degree. C. in the presence of a base such as
triethylamine.
[0048] Diols (5) are obtainable by sequential treatment of ketones
(6) with ozone and sodium borohydride: ##STR9## where Ar.sup.1 and
Ar.sup.2 have the same meanings as before. The ozonolysis is
typically carried out at about -78.degree. C. in a
dichloromethane/methanol mixture, then sodium borohydride added
with warming to ambient temperature.
[0049] Ketones (6) are obtained by alkylation of cyclohexanones (7)
with allyl bromide or allyl iodide: ##STR10## where Ar.sup.1 and
Ar.sup.2 have the same meanings as before. The reaction may be
carried out in THF at -78.degree. C. in the presence of strong base
such as lithium hexamethyldisilazide. As an alternative to lithium
hexamethyldisilazide, there may be employed the product obtained
from reacting BuLi with a chiral amine such as
[S--(R*,R*)]-(-)-bis(.alpha.-methylbenzyl)amine. This enables the
isolation of compounds (6) in homochiral form, and hence the
synthesis of homochiral compounds of formula I. The preparation of
cyclohexanones (7) is described in WO 02/081435 and WO
04/013090.
[0050] Detailed procedures for this and other routes to the
compounds of formula I are provided in the Examples section.
[0051] It will be apparent to those skilled in the art that
individual compounds of formula I prepared by the above routes may
be converted into other compounds in accordance with formula I by
means of well known synthetic techniques such as alkylation,
esterification, amide coupling, hydrolysis, coupling mediated by
organometallic species, oxidation and reduction. Such techniques
may likewise be carried out on precursors of the compounds of
formula I. For example, substituents on the aromatic groups
Ar.sup.1 or Ar.sup.2 may be added or interconverted by means of
standard synthetic processes carried out on the compounds of
formula I or their precursors. For example, a chlorine or bromine
atom on Ar.sup.1 or Ar.sup.2 may be replaced by vinyl by treatment
with vinyltributyltin in the presence of tri-t-butylphosphine,
cesium fluoride and tris(dibenzylideneacetone)dipalladium(0).
Ozonolysis of the vinyl group provides the corresponding formyl
derivative, which may be transformed in a variety of ways,
including oxidation to the corresponding acid, reduction to the
corresponding benzyl alcohol, and conversion to the corresponding
nitrile by treatment with hydroxylamine then triphenylphosphine and
carbon tetrachloride.
[0052] Similarly, compounds of formula I in which R.sup.3 is
alkenyl such as allyl may be subjected to ozonolysis and further
transformation in the manner described in the previous
paragraph.
[0053] Where they are not themselves commercially available, the
starting materials and reagents employed in the above-described
synthetic schemes may be obtained by the application of standard
techniques of organic synthesis to commercially available
materials.
[0054] It will be appreciated that many of the above-described
synthetic schemes may give rise to mixtures of stereoisomers. Such
mixtures may be separated by conventional means such as fractional
crystallisation and preparative chromatography.
[0055] Certain compounds according to the invention may exist as
optical isomers due to the presence of one or more chiral centres
or because of the overall asymmetry of the molecule. Such compounds
may be prepared in racemic form, or individual enantiomers may be
prepared either by enantiospecific synthesis or by resolution. The
novel compounds may, for example, be resolved into their component
enantiomers by standard techniques such as preparative HPLC, or the
formation of diastereomeric pairs by salt formation with an
optically active acid, such as di-p-toluoyl-D-tartaric acid and/or
di-p-toluoyl-L-tartaric acid, followed by fractional
crystallisation and regeneration of the free base. The novel
compounds may also be resolved by formation of diastereomeric
esters or amides, followed by chromatographic separation and
removal of the chiral auxiliary.
[0056] During any of the above synthetic sequences it may be
necessary and/or desirable to protect sensitive or reactive groups
on any of the molecules concerned. This may be achieved by means of
conventional protecting groups, such as those described in
Protective Groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum
Press, 1973; and T. W. Greene & P. G. M. Wuts, Protective
Groups in Organic Synthesis, John Wiley & Sons, 3.sup.rd ed.,
1999. The protecting groups may be removed at a convenient
subsequent stage using methods known from the art.
[0057] An assay which can be used to determine the level of
activity of compounds of the present invention is described in
WO01/70677. A preferred assay to determine such activity is
described in WO 03/093252.
[0058] Alternative assays are described in Biochemistry, 2000,
39(30), 8698-8704.
[0059] See also, J. Neuroscience Methods, 2000, 102, 61-68.
[0060] The Examples of the present invention all had an ED.sub.50
of less than 0.5 .mu.M, typically less than 50 nM, in most cases
less than 10 nM, and in preferred cases less than 1.0 nM, in at
least one of the above assays.
[0061] The following examples illustrate the present invention. For
the sake of convenience, compounds are depicted as being in
accordance with formula IA even if they are racemic. Homochiral
compounds are indicated by means of R and S configurational
descriptors.
EXAMPLES
Intermediate 1
4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)-2-[2-(trimethylsilyl)e-
thoxymethyl]cyclohexanone
[0062] ##STR11##
[0063]
4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanone
(WO 02/081435) (2.0 g, 5.2 mmol) in dry tetrahydrofuran (10 mL) was
added dropwise to a cooled solution of 0.5 M lithium
hexamethyldisilazide in tetrahydrofuran (11.4 mL) at -78.degree. C.
The mixture was stirred at this temperature for 2 hours before
adding 2-(trimethylsilyl)ethoxymethyl chloride (1.4 mL, 7.8 mmol)
and the solution allowed to warm to rt. over 16 hours. The reaction
mixture was diluted with ethyl acetate (10 mL), washed with water
(10 mL), and the organic phase separated, dried (MgSO.sub.4) and
evaporated to dryness. The product was purified on silica eluting
with [9:1] hexane-ethyl acetate to yield 1.2 g of the title
compound. .sup.1H NMR CDCl.sub.3 7.38 (4H, s), 7.24-7.16 (1H, m),
7.12-7.06 (1H, m), 6.97-6.87 (1H, m), 3.66 (1H, dd, J=9.7 and 3.0
Hz), 3.51-3.45 (3H, m), 3.17-3.15 (1H, m), 3.05-2.98 (1H, m),
2.56-2.49 (2H, m), 2.41-2.35 (2H, m), 2.23-2.17 (1H, m), 0.91-0.87
(2H, m) and 0.03 (9H, s).
Intermediate 2
4-[(4-Trifluoromethylphenyl)sulfonyl]-4-(2,5-difluorophenyl)-2-[2-(trimeth-
ylsilyl)ethoxymethyl]cyclohexanone
[0064] ##STR12##
[0065] Prepared as for Intermediate 1, starting from
4-[(4-trifluoromethylphenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanone
(WO 02/081435), and obtained as a solid. .sup.1H NMR CDCl.sub.3
7.69-7.59 (4H, m), 7.24-7.18 (1H, m), 7.12-7.06 (1H, m), 6.93-6.86
(1H, m), 3.67 (1H, dd, J=9.7 and 2.9 Hz), 3.58-3.47 (3H, m),
3.20-3.16 (1H, m), 3.04-2.98 (1H, m), 2.57-2.51 (2H, m), 2.41-2.38
(2H, m), 2.24-2.16 (1H, m), 0.91-0.87 (2H, m) and 0.03 (9H, s).
Intermediate 3
(R,S)-4-[(4-Trifluoromethylphenyl)sulfonyl]-4-(2,5-difluorophenyl)-2-[2-(t-
rimethylsilyl)ethoxymethyl]cyclohexanone
[0066] ##STR13##
[0067] [(S--(R*,R*)]-(-)-Bis(.alpha.-methylbenzyl)amine (10 g, 44.4
mmol) and anhydrous lithium chloride (1.87 g, 44.5 mmol) were
stirred in tetrahydrofuran (250 mL) under nitrogen gas, then cooled
to -78.degree. C. and treated slowly with butyllithium (1.6 mol
solution in hexanes, 25.9 mL). The reaction mixture was allowed to
warm up to 0.degree. C. and stirred for 30 min. then re-cooled to
an internal temperature of -100.degree. C., stirring for 1 h. A
solution of
4-[(4-trifluoromethylphenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanone
(WO 02/081435) (12.5 g, 29.9 mmol) in tetrahydrofuran (50 mL),
cooled to -78.degree. C., was added slowly, maintaining the
internal temperature at -100.degree. C. The mixture was stirred at
-100.degree. C. for 2 h., then 2-(trimethylsilyl)ethoxymethyl
chloride (7.9 mL, 44.7 mmol) was added, the resulting mixture
warmed to -78.degree. C., and allowed to warm up slowly overnight
to -12.degree. C. The reaction mixture was quenched with a 1M
solution of citric acid then extracted with ethyl acetate. The
organic extracts were washed with a 1M citric acid, 5% sodium
bicarbonate solution, dried (MgSO.sub.4), filtered and the solvent
was removed. The resulting oil was purified by column
chromatography on silica gel eluting with 2 to 10% ethyl
acetate:isohexane to give the title compound as a clear oil. Yield
5 g (30%).
[0068] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.69 (2H, d, J 8.4
Hz), 7.60 (2H, d, J 8.4 Hz), 7.23-7.18 (1H, m), 7.15-7.08 (1H, m),
6.96-6.86 (1H, m), 3.70-3.64 (1H, m), 3.53-3.48 (3H, m), 3.22-3.16
(1H, m), 3.08-2.98 (1H, m), 2.61-2.51 (2H, m), 2.43-2.36 (2H, m),
2.25-2.14 (1H, m), 0.94-0.83 (2H, m), 0.00 (9H, s). Chiral purity
determined by chiral HPLC.
Intermediate 4 (R, S)
(R,S)-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)-2-[2-(trimethyls-
ilyl)ethoxymethyl]cyclohexanone
[0069] ##STR14##
[0070] Prepared in the same manner as Intermediate 3 using the
4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanone as
starting material. NMR data as for Intermediate 1.
Example 1
[0071]
(4aRS,6RS,8aSR)-6-(2,5-difluorophenyl)-6-{[4-(trifluoromethyl)phen-
yl]sulfonyl}octahydro-1H-2,1-benzothiazine 2,2-dioxide Step 1
##STR15##
[0072] Intermediate 2 in isopropanol was treated with NaBH.sub.4 (4
equiv.) at -40.degree. C. and stirred whilst allowing to warm to
rt. over 16 hours. The reaction was quenched with 8% aqueous citric
acid, diluted with ethyl acetate, then the organic phase was
separated, dried (MgSO.sub.4) and evaporated to dryness. The trans
product was purified on silica eluting with hexane-ethyl acetate
mixtures. Step 2 ##STR16##
[0073] The alcohol from Step 1 in dichloromethane (100 mL) was
treated with triethylamine (2 equiv.) at 0.degree. C. and stirred
whilst methanesulfonyl chloride (1.2 equiv.) was added. The
reaction mixture was allowed to warm to r.t. over 1 hour, washed
with water, 10% aqueous citric acid and saturated aqueous sodium
hydrogen carbonate, then dried (MgSO.sub.4) and evaporated to
dryness. The residue was filtered through silica eluting with 20%
ethyl acetate in hexanes to give the mesylate.
[0074] This solid in dimethylformamide was treated with sodium
azide (approx. 2-fold excess) and heated to 95.degree. C. for 8
hrs. The mixture was treated with water and extracted twice with
ethyl acetate. The combined organics were washed with brine, dried
(MgSO.sub.4) and evaporated to dryness. The residue, in
tetrahydrofuran and water (10:1 v/v), was treated with
triphenylphosphine (1.2 equiv.) at room temperature for 15 mins and
then the mixture was heated at reflux for 4 hrs. The mixture was
allowed to cool to rt. and then passed through SCX Varian Bond
Elut.TM. cartridge. The basic fraction was evaporated to give the
primary amine. .sup.1H NMR CDCl.sub.3 7.67-7.55 (4H, m), 7.09-7.00
(2H, m), 6.85-6.77 (1H, m), 3.51-3.16 (5H, m), 2.65-2.29 (4H, m),
1.76-1.71 (3H, m), 0.93-0.89 (2H, m) and 0.03 (9H, s). MS MH.sup.+
550. Step 3 ##STR17##
[0075] Triethylamine (175 .mu.L, 1.26 mmol) was added to a solution
of the product of Step 2 (230 mg, 0.419 mmol) and methanesulfonyl
chloride (65 .mu.L, 0.838 mmol) in dichloromethane (5 mL). The
mixture was stirred at room temperature for 3 h., evaporated to
dryness and the residue partitioned between ethyl acetate and 2 M
hydrochloric acid. The organic layer was washed with 2 M
hydrochloric acid, and then 4 M sodium hydroxide, dried
(MgSO.sub.4), filtered and the solvent removed to give the desired
methanesulfonamide as a light yellow foam. Yield 263 mg. .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 7.64 (2H, d, J 8.3 Hz), 7.51 (2H,
d, J 8.3 Hz), 7.05-7.02 (2H, m), 6.82-6.72 (1H, m), 5.66 (1H, brs),
3.69-3.66 (1H, m), 3.50-3.43 (4H, m), 2.96 (3H, s), 2.70-2.64 (1H,
m), 2.55-2.42 (2H, m), 2.38-2.29 (1H, m), 2.19-2.11 (1H, m),
1.72-1.63 (1H, m), 1.40-1.31 (1H. m), 0.95-0.89 (2H, m), 0.00 (9H,
s). Step 4 ##STR18##
[0076] The product of Step 3 (263 mg, 0.419 mmol) in
dimethylformamide (5 mL) was treated with sodium hydride (60%
dispersion in mineral oil, 90 mg, 2.25 mmol), the mixture was
stirred at room temperature for 30 min., then allyl bromide (382
.mu.L, 4.51 mmol) was added, and the mixture heated to 65.degree.
C. and stirred overnight. The cooled mixture was quenched with
water and extracted with ethyl acetate. The organic extract was
washed with water, dried (MgSO.sub.4), filtered and the solvent was
removed. The residue was purified by column chromatography on
silica gel eluting with 25% ethyl acetate:75% isohexane to give the
N-allyl derivative as a yellow foam. Yield 150 mg.
[0077] .sup.1H NMR (360 MHz, CDCl.sub.3) .delta. 7.83 (2H, d, J 8.3
Hz), 7.72 (2H, d, J 8.3 Hz), 7.25-7.19 (2H, m), 7.04-6.97 (1H, m),
6.16-6.07 (1H, m), 5.59 (1H, d, J 17.4 Hz), 5.48 (1H, d, J 10.3
Hz), 4.39-4.22 (2H, m), 4.18-4.15 (1H, m), 3.78-3.73 (1H, m),
3.66-3.61 (2H, m), 3.53-3.48 (1H, m), 3.02 (3H, s), 2.94-2.90 (1H,
m), 2.84-2.82 (2H, m), 2.63-2.55 (1H, m), 2.28-2.21 (1H, m),
2.10-2.04 (1H, m), 1.99-1.92 (1H, m), 1.09-1.02 (2H, m), 0.17 (9H,
s). Step 5 ##STR19##
[0078] The product of Step 4 (150 mg, 0.225 mmol) in
dichloromethane was treated with boron trifluoride diethyl etherate
(250 .mu.L, 1.99 mmol) and after 2 hours the mixture was cooled to
0.degree. C. and stirred during the addition of sodium hydroxide
(2.5M). The layers were separated and the organics were washed with
brine, dried (MgSO.sub.4) and evaporated to give an oil which was
azeotroped with heptane to give the alcohol (115 mg).
[0079] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. 7.67 (2H, d, J 8.2
Hz), 7.53 (2H, d, J 8.2 Hz), 7.08-7.06 (2H, m), 7.11-7.05 (1H, m),
6.00-5.91 (1H, m), 5.49 (1H, d, J 17.2 Hz), 5.37 (1H, d, J 10.4
Hz), 4.31-4.25 (1H, m), 4.20-4.10 (1H, m), 4.06-4.02 (1H, m),
3.88-3.81 (1H, m), 3.47-3.41 (1H, m), 3.40-3.38 (1H, m), 2.88 (3H,
s), 2.69-2.62 (1H, m), 2.55-2.46 (1H, m), 2.35-2.26 (1H, m),
2.13-2.06 (1H, m), 1.95-1.87 (1H, m), 1.85-1.75 (1H, m). Step 6
##STR20##
[0080] The alcohol from Step 5 (115 mg, 0, 203 mmol) and
methanesulfonyl chloride (47 .mu.L, 0.609 mmol) in dichloromethane
(5 mL) were treated with triethylamine (141 .mu.L, 1.01 mmol) and
the mixture stirred at room temperature for 3 h. The solvent was
removed under reduced pressure, and the residue partitioned between
ethyl acetate and 2 M hydrochloric acid. The organics were
collected, washed with 2 M hydrochloric acid, and then 4 M sodium
hydroxide, dried (MgSO.sub.4), filtered and the solvent was
removed, azeotroping with toluene to remove all traces of ethyl
acetate, to give the mesylate as a white foam. Yield 130 mg. Step 7
##STR21##
[0081] The mesylate from Step 6 (130 mg, 0.202 mmol) in
tetrahydrofuran (5 mL) at -30.degree. C. under nitrogen gas was
treated with butyllithium (1.6 M solution in hexanes, 252 .mu.L)
and the reaction mixture was allowed to warm up slowly to room
temperature, then quenched with water and extracted with ethyl
acetate. The organic extract was washed with water, dried
(MgSO.sub.4), filtered and evaporated. The residue was purified by
column chromatography on silica gel eluting with 25% ethyl
acetate:75% isohexane to give the desired cyclic sulfonamide as a
white powder. Yield 15 mg (14%).
[0082] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. 7.67 (2H, d, J 8.1
Hz), 7.53 (2H, d, J 8.1 Hz), 7.12-7.06 (2H, m), 6.88-6.77 (1H, m),
6.07-5.98 (1H, m), 5.28 (1H, dd, J 0.5 and 17.6 Hz), 5.23 (1H, dd,
J 0.5 & 10.5 Hz), 4.41-4.31 (1H, m), 3.71-3.61 (1H, m),
3.28-3.20 (1H, m), 3.10-3.02 (1H, m), 2.91-2.80 (1H, m), 2.56-2.25
(5H, m), 1.98-1.90 (1H, m), 1.81-1.66 (1H, m), 1.45-1.30 (2H,
m).
Step 8
[0083] The product of Step 7 (12 mg, 0.022 mmol) in toluene (2 mL)
was treated with
[1.3-bis(diphenylphosphino)propane]dichloronickel(II) (1.2 mg,
0.0022 mmol) then diisobutylaluminum hydride (1.5 M solution in
toluene, 30 .mu.L). The mixture was stirred at room temperature for
3 h., then quenched with 4 M sodium hydroxide and extracted with
ethyl acetate. The organic extracts were dried (MgSO.sub.4),
filtered through a plug of silica gel eluting with ethyl acetate
and evaporated to dryness. The residue was triturated in diethyl
ether and the solid was collected to give the title compound as a
white solid. Yield 6 mg (55%).
[0084] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. 7.67 (2H, d, J 8.1
Hz), 7.53 (2H, d, J 8.1 Hz), 7.12-7.07 (2H, m), 6.90-6.78 (1H, m),
4.45-4.37 (1H, m), 3.76-3.71 (1H, m), 3.20-3.11 (1H, m), 3.10-3.04
(1H, m), 2.71-2.61 (1H, m), 2.55-2.42 (2H, m), 2.40-2.29 (1H, m),
2.10-1.98 (1H, m), 1.91-1.84 (1H, m), 1.72-1.60 (2H, m), 0.98-0.91
(1H, m). m/z (ES.sup.-) (M-1) 508.
Example 2
(3S,4aR,6R,8aS)-6-(2,5-difluorophenyl)-3-ethyl-6-{[4-(trifluoromethyl)phen-
yl]sulfonyl}octahydro-1H-2,1-benzothiazine 2,2-dioxide
[0085] Step 1 ##STR22##
[0086] Intermediate 3 (830 mg, 1.29 mmol) was treated as described
in Example 1 Steps 1-7 to give the chiral N-allyl sulfonamide as a
white solid. Yield 300 mg (42%).
[0087] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. 7.67 (2H, d, J 8.1
Hz), 7.53 (2H, d, J 8.1 Hz), 7.12-7.06 (2H, m), 6.88-6.77 (1H, m),
6.07-5.98 (1H, m), 5.28 (1H, dd, J 0.5 and 17.6 Hz), 5.23 (1H, dd,
J 0.5 and 10.5 Hz), 4.41-4.31 (1H, m), 3.71-3.61 (1H, m), 3.28-3.20
(1H, m), 3.10-3.02 (1H, m), 2.91-2.80 (1H, m), 2.56-2.25 (5H, m),
1.98-1.90 (1H, m), 1.81-1.66 (1H, m), 1.45-1.30 (2H, m). Step 2
##STR23##
[0088] The product of Step 1 (80 mg, 0.146 mmol) in tetrahydrofuran
(5 mL) at 0.degree. C. was treated with lithium
bis(trimethylsilyl)amide (1M solution in tetrahydrofuran, 292
.mu.L) and the mixture was stirred at 0.degree. C. for 30 min.
before addition of iodoethane (15 .mu.L, 0.188 mmol). The resulting
mixture was allowed to warm up slowly overnight, quenched with
water then extracted with ethyl acetate. The organic extracts were
dried (MgSO.sub.4), filtered and the solvent was removed. The
residue was purified by column chromatography on silica gel eluting
with 10 to 15% ethyl acetate:isohexane to give a less polar product
(white solid, yield 28 mg, 33%):
[0089] .sup.1H NMR (500 MHz, CD.sub.3OH) .delta.7.81 (2H, d, J 8.3
Hz), 7.66 (2H, d, J 8.3 Hz), 7.24-7.15 (2H, m), 7.02-6.93 (1H, m),
6.04-5.93 (1H, m), 5.32 (1H, d, J 17.2 Hz), 5.19 (1H, d, J 10.1
Hz), 4.26 (1H, dd, J 5.1 & 17.2 Hz), 3.77 (1H, dd, J 7.0 &
17.2 Hz), 3.54 (1H, brs), 3.16-3.11 (1H, m), 2.83-2.68 (1H, m),
2.61-2.39 (2H, m), 2.33-2.02 (2H, m), 2.08-1.85 (2H, m), 1.55-1.28
(3H, m), 1.11-0.98 (3H, m), 0.93-0.82 (1H, m);
and also a more polar product (white solid, yield 23 mg 27%):
[0090] .sup.1H NMR (500 MHz, CD.sub.3OH) .delta. 7.83 (2H, d, J 8.3
Hz), 7.66 (2H, d, J 8.3 Hz), 7.24-7.14 (2H, m), 7.04-6.94 (1H, m),
5.92-5.81 (1H, m), 5.24 (1H, dd, J 1.1 & 17.2 Hz), 5.13 (1H,
dd, J 1.1 & 10.3 Hz), 4.13-4.05 (1H, dd, m), 3.75 (1H, dd, J
6.8 & 16.7 Hz), 3.59-3.53 (1H, m), 3.00-2.93 (1H, m), 2.70-2.55
(2H, m), 2.48-2.22 (4H, m), 2.13-2.03 (1H, m), 1.93-1.85 (1H, m),
1.75-1.66 (1H, m), 1.59-1.47 (1H, m), 1.17-1.07 (3H, m), 0.95-0.84
(1H, m).
Step 3
[0091] The less polar product from Step 2 (25 mg, 0.0433 mmol) was
treated as described in Example 1 Step 8 to give the desired chiral
sulfonamide as a white solid. Yield 20 mg (86%).
[0092] .sup.1H NMR (500 MHz, CD.sub.3OH) .delta. 7.82 (2H, d, J 8.2
Hz), 7.64 (2H, d, J 8.2 Hz), 7.23-7.08 (2H, m), 7.01-6.93 (1H, m),
3.57-3.52 (1H, m), 3.06-2.98 (1H, m), 2.75-2.56 (2H, m), 2.51-2.37
(2H, m), 2.00-1.91 (2H, m), 1.90-1.82 (1H, m), 1.74-1.55 (2H, m),
1.51-1.42 (1H, m), 1.23-1.20 (1H, m), 1.15-1.07 (3H, m), 0.97-0.84
(1H, m). m/z (ES.sup.-) (M-1) 536.
Example 3
(3R,4aR,6R,8aS)-6-(2,5-difluorophenyl)-3-ethyl-6-{[4-(trifluoromethyl)phen-
yl]sulfonyl}octahydro-1H-2,1-benzothiazine 2,2-dioxide
[0093] ##STR24##
[0094] The more polar isomer from Example 2 Step 2 (23 mg, 0.0433
mmol) was treated as described in Example 1 Step 8 to give the
desired chiral sulfonamide as a white solid. Yield 10 mg (46%).
[0095] .sup.1H NMR (500 MHz, CD.sub.3OH) .delta. 7.84 (2H, d, J 8.2
Hz), 7.65 (2H, d, J 8.2 Hz), 7.27-7.08 (2H, m), 7.04-6.94 (1H, m),
3.62-3.57 (1H, m), 2.93-2.86 (1H, m), 2.75-2.63 (1H, m), 2.56-2.49
(2H, m), 2.48-2.41 (1H, m), 2.40-2.32 (1H, m), 2.17-2.07 (1H, m),
2.00-1.93 (1H, m), 1.91-1.84 (1H, m), 1.79-1.70 (1H, m), 1.68-1.55
(1H, m), 1.32-1.25 (1H, m), 1.20-1.14 (3H, m), 0.98-0.85 (1H, m).
m/z (ES.sup.-) (M-1) 536.
Example 4
(3RS,4aRS,6RS,8aSR)-6-(2,5-difluorophenyl)-3-isopropyl-6-{[4-(trifluoromet-
hyl)phenyl]sulfonyl}octahydro-1H-2,1-benzothiazine 2,2-dioxide
[0096] Step 1 ##STR25##
[0097] The product from Example 1 Step 2 was treated with boron
trifluoride etherate as described in Example 1 Step 5. The
resulting alcohol (2 g, 3.1 mmol) in dichloromethane (25 mL) was
treated with triethylamine (1.7 mL, 12.4 mmol),
4-dimethylaminopyridine (cat.) and butyldimethylsilyl chloride
(1.16 g, 7.75 mmol). After 16 hours the mixture was washed with 10%
citric acid (10 mL), sodium bicarbonate (sat., 20 mL) and brine
(sat. 15 mL). The organics were dried (MgSO.sub.4) and evaporated
and the residue was filtered through silica eluting with 1% ammonia
in ethyl acetate to give the desired t-butyldimethylsilyl ether as
a white solid (1.8 g) MS ES+564. Step 2 ##STR26##
[0098] The silyl ether from Step 1 (1.8 g, 3.2 mmol) and
isobutanesulfonyl chloride (1.12 g, 8 mmol) were stirred in
dichloromethane (20 mL) and triethylamine (1.34 mL, 9.5 mmol) was
added. After stirring at room temperature for 16 h., the mixture
was evaporated to dryness and the residue was partitioned between
ethyl acetate and 2 M hydrochloric acid. The organic layer was
collected, washed with 2 M hydrochloric acid and then 4 M sodium
hydroxide, dried (MgSO.sub.4), filtered and the solvent removed in
vacuo. The residue was purified by column chromatography (eluting
with 20% ethyl acetate in hexanes) to give the sulfonamide (900
mg). This product was dissolved in dimethylformamide (6 mL) and
sodium hydride (60% dispersion in mineral oil, 132 mg, 3.3 mmol)
was added. The mixture was stirred at room temperature for 30 min.,
allyl bromide (1.1 mL, 13 mmol) was added, then the mixture was
heated to 65.degree. C. over 72 hrs. After cooling to room
temperature and quenching with water, the mixture was extracted
with ethyl acetate. The organic extract was washed with water,
dried (MgSO.sub.4), filtered and the solvent was removed. The
residue was purified by column chromatography on silica gel eluting
with 20% ethyl acetate:80% isohexane to give the N-allyl derivative
(400 mg). .sup.1H NMR (360 MHz, CDCl.sub.3) .delta. 7.67 (2H, d, J
8.3 Hz), 7.52 (2H, d, J 8.3 Hz), 7.10-7.05 (2H, m), 6.85-6.79 (1H,
m), 5.96-5.91 (1H, m), 5.45 (1H, d, J 17.3 Hz), 5.34 (1H, d, J 10.4
Hz), 4.22-4.09 (1H, m), 4.01-3.98 (1H, m), 3.86-3.81 (1H, m),
3.51-3.40 (2H, m), 2.88-2.63 (4H, m), 2.49-2.43 (1H, m), 2.32-2.24
(2H, m), 2.09-2.04 (1H, m), 1.95-1.72 (2H, m) and 1.11-1.03 (6H,
m). Step 3 ##STR27##
[0099] Prepared from the product of Step 2 (0.2 g) and
p-toluenesulfonyl chloride (3 equiv.) in pyridine in the presence
of 4-dimethylaminopyridine (0.3 equiv.) at 40.degree. C. After
extractive work-up, purification by column chromatography on
silica, eluting with 30% ethyl acetate in hexanes gave the tosylate
(185 mg). Step 4 ##STR28##
[0100] The tosylate from Step 3 (186 mg, 0.24 mmol) in
tetrahydrofuran (9 mL) at -40.degree. C. under nitrogen was treated
with lithium hexamethyldisilazide (1.0 M solution in
tetrahydrofuran, 480 .mu.L) and the reaction mixture was allowed to
warm up slowly to room temperature, then quenched with saturated
aqueous ammonium chloride and extracted with ethyl acetate. The
organic extract was washed with water, dried (MgSO.sub.4), filtered
and the solvent was removed. The residue was purified by column
chromatography on silica gel eluting with 15% ethyl acetate:85%
isohexane. to give a less polar product as a white solid (48
mg):
[0101] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. 7.66 (2H, d, J 8
Hz), 7.52 (2H, d, J 8 Hz), 7.11-7.07 (1H, m), 6.93-6.75 (2H, m),
6.06-5.96 (1H, m), 5.29-5.22 (2H, m), 4.41-4.33 (1H, m), 3.69-3.48
(2H, m), 3.07-2.99 (1H, m), 2.89-2.72 (1H, m), 2.61-2.20 (5H, m),
1.90-1.73 (2H, m), 1.48-1.30 (2H, m), 1.17 (3H, d, J=7 Hz) and 1.05
(3H, d, J=7 Hz);
and also a more polar product as a white solid. (67 mg):
[0102] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta.7.65 (2H, d, J 8
Hz), 7.54 (2H, d, J 8 Hz), 7.07-7.03 (2H, m), 6.86-6.78 (1H, m),
5.75-5.65 (1H, m), 5.04-4.99 (2H, m), 3.95 (1H, dd, J=15.5 and 4.5
Hz), 3.63 (1H, dd, J=15.5 and 6.5 Hz), 3.29-3.24 (1H, m), 2.76-2.72
(1H, m), 2.61-2.52 (4H, m), 2.49-2.42 (1H, m), 2.40-2.18 (3H, m),
2.09-2.00 (1H, m), 1.75-1.68 (1H, m), 1.17 (3H, d, J=6.8 Hz) and
1.09 (3H, d, J=6.8 Hz).
Step 5
[0103] The less polar product from Step 4 (40 mg, 0.067 mmol) was
treated as described in Example 1 Step 8 to give the title compound
as a white solid. 23 mg. .sup.1H NMR (500 MHz, CDCl.sub.3)
.delta.7.67 (2H, d, J 8.3 Hz), 7.53 (2H, d, J 8.0 Hz), 7.25-6.88
(2H, m), 7.11-7.06 (1H, m), 4.68-4.50 (1H, brs), 3.69-3.68 (1H, m),
3.00-2.96 (1H, m), 2.71-2.65 (1H, m), 2.60-2.27 (3H, m), 2.18-2.13
(1H, m), 2.02-1.87 (2H, m), 1.80-1.52 (3H, m), 1.22 (3H, d, J 6.9
Hz), 1.07 (3H, d, J 6.9 Hz). m/z (ES.sup.-) (M-1) 550.
Example 5
(3SR,4aRS,6RS,8aSR)-6-(2,5-difluorophenyl)-3-isopropyl-6-{[4-(trifluoromet-
hyl)phenyl]sulfonyl}octahydro-1H-2,1-benzothiazine 2,2-dioxide
[0104] ##STR29##
[0105] Step 5 of Example 4 was repeated, using the more polar
isomer from Step 4 (40 mg, 0.067 mmol) to give the title compound
as a white solid. (23 mg). .sup.1H NMR (500 MHz, CDCl.sub.3)
.delta.7.68 (2H, d, J 8.3 Hz), 7.54 (2H, d, J 8.2 Hz), 7.10-7.06
(2H, m), 6.87-6.82 (1H, m), 4.47 (1H, d, J 8.9 Hz), 3.60-3.57 (1H,
m), 2.82-2.77 (1H, m), 2.71-2.52 (2H, m), 2.40-2.20 (4H, m), 1.98
(1H, dd, J 15.1 and 2 Hz), 1.81-1.77 (2H, m), 1.76-1.74 (1H, m),
1.26 (3H, d, J 6.4 Hz), 1.11 (3H, d, J 6.8 Hz). m/z (ES.sup.-)
(M-1) 550.
Example 6
(3S,4aR,6R,8aS)-6-[(4-chlorophenyl)sulfonyl]-6-(2,5-difluorophenyl)-3-ethy-
loctahydro-1H-2,1-benzothiazine 2,2-dioxide
[0106] Step 1 ##STR30##
[0107] Intermediate 4 was treated as described in Example 1 Steps 1
and 2. The resulting product (80% e.e) (3.6 g, 6.96 mmol) was
dissolved in iso-propanol (34 mL) and (1S)-(+)-camphor sulfonic
acid (1.37 g, 5.91 mmol) was added. The mixture was heated to
reflux, allowed to cool to room temperature slowly, and then left
in the refrigerator overnight. The resulting solid was collected,
washed with pre-cooled (.about.5.degree. C.) isopropanol, then
suspended in ethyl acetate and washed with 4M sodium hydroxide. The
organics were dried (MgSO.sub.4), filtered and the solvent removed
to give the chiral amine (98% e.e). Yield 3 g, .sup.1H NMR
CDCl.sub.3 7.39-7.31 (4H, m), 7.09-6.96 (2H, m), 6.85-6.80 (1H, m),
3.48-3.15 (5H, m), 2.93-2.29 (4H, m), 1.74-1.19 (3H, m), 0.93-0.89
(2H, m) and 0.03 (9H, s). MS MH+516(518).
Step 2
[0108] The amine from Step 1 (3 g) was elaborated as described for
Example 1 Steps 3-8 to provide the desired homochiral sulfonamide
(60 mg).
[0109] .sup.1H NMR (500 MHz, CD.sub.3OH) .delta. 77.51 (2H, d, J
8.7 Hz), 7.40 (2H, d, J 7.9 Hz), 7.25-7.11 (2H, m), 7.04-6.94 (1H,
m), 3.55-3.51 (1H, m), 3.03-2.97 (1H, m), 2.75-2.32 (4H, m),
2.17-2.07 (1H, m), 2.01-1.93 (2H, m), 1.91-1.84 (1H, m), 1.75-1.57
(2H, m), 1.50-1.44 (1H, m) and 1.11 (3H, t, J 7.6 Hz).
Example 7
(3S,4aR,6R,8aS)-6-(2,5-difluorophenyl)-3-ethyl-6-{[4-(trifluoromethyl)phen-
yl]sulfonyl}octahydro-1H-2,1-benzothiazine 2,2-dioxide
[0110] ##STR31##
[0111] alternative route. Step 1 ##STR32##
[0112] A solution of (1S)-1-phenyl-N-[(1S)-1-phenylethyl]ethanamine
(10.8 g, 47.85 mmol) and oven-dried lithium chloride (3.0 g, 71.80
mmol) in tetrahydrofuran (200 ml) was degassed under nitrogen. The
reaction mixture was cooled to -78.degree. C. (internal
temperature) and treated with n-butyl lithium (1.6M in hexane, 30
ml, 47.85 mmol), dropwise over 25 minutes. After the addition, the
reaction was warmed to -20.degree. C. and then cooled to
-100.degree. C. and stirred for 2 hours. A solution of
4-(2,5-difluorophenyl)-4-[[4-(trifluoromethyl)phenyl]sulfonyl]-cyclohexan-
one (20 g, 47.85 mmol) in tetrahydrofuran (100 ml) (cooled to
-78.degree. C.) was cannulated into the reaction vessel over 20
minutes. After a further 30 minutes at -100.degree. C., allyl
iodide (8.80 ml, 95.60 mmol) was added and the reaction mixture was
allowed to warm to room temperature over 18 hours. The reaction
mixture was acidified with citric acid solution (200 ml) and
diluted with ethyl actetate (300 ml). The ethyl acetate layer was
separated and re-washed with citric acid solution (200 ml), 10%
ammonia solution (200 ml), brine, dried over MgSO.sub.4, filtered
and evaporated in vacuo. Purification by column chromatography gave
the title compound as a white solid (8.97 g, 41%, 70% ee).
[0113] A solution of this material (73.1 g, 61% ee) in toluene (181
ml) was added dropwise to isohexane (760 ml) stirring at 70.degree.
C., over 45 minutes. The reaction mixture was seeded with racemic
product (100 mg) and was cooled slowly over 21/2 hours. The
resultant solid was filtered and the filtrate was evaporated in
vacuo resulting in clear gummy oil (49 g, 95% ee). Step 2
##STR33##
[0114] Oxygen was bubbled through a stirred solution of the product
of Step 1 (67.8 g, 148 mmol) in dichloromethane (750 ml) and
methanol (150 ml) at -78.degree. C. for 10 minutes. Ozone was
bubbled into the reaction mixture until a blue coloration persisted
(31/2 hours), followed by oxygen and then nitrogen until the blue
color disappeared. Sodium borohydride (14 g, 370 mmol) was added to
the reaction mixture, which was then allowed to warm to room
temperature slowly. The mixture was acidified with citric acid
solution (200 ml) and 2N hydrochloric acid, until pH 2, and diluted
with dichloromethane (800 ml). The dichloromethane layer was
separated and washed with water, brine, dried over MgSO.sub.4,
filtered and evaporated in vacuo. Purification by recrystallization
from ether and isohexane (50:50), gave the diol as a white solid
(50 g, 73%, 97% ee). Step 3 ##STR34##
[0115] Methanesulfonyl chloride (20 ml, 259 mmol) was added slowly
to a solution of the product of Step 2 (50 g, 108 mmol) in
dichloromethane (700 ml) and triethylamine (45 ml, 324 mmol),
stirring at -10.degree. C. The reaction mixture was allowed to stir
at -10.degree. C. for 2 hours. The reaction was acidified with
citric acid solution (500 ml) and diluted with dichloromethane (500
ml). The dichloromethane layer was separated and washed with sodium
hydrogen carbonate solution (500 ml), brine, dried over MgSO.sub.4,
filtered and evaporated in vacuo to give the bis-mesylate as white
foam (67.7 g, >100%), which was used without further
purification. Step 4 ##STR35##
[0116] A solution of the product of Step 3 (67.7 g, 109 mmol) in
ethanol was treated with thiourea (8.7 g, 115 mmol). The reaction
mixture was stirred at 80.degree. C. for 18 hours, cooled to room
temperature and evaporated in vacuo to give the desired product as
pale yellow foam (80.6 g, >100%). Step 5 ##STR36##
[0117] Acetic acid (500 ml) was added to a solution of the product
of Step 4 (80.7 g) in water (100 ml) at room temperature. Chlorine
gas (approximately 55 g) was bubbled through the reaction mixture
for 30 minutes, until the reaction mixture turned a dark yellow.
The reaction mixture was diluted with diethyl ether (1000 ml) and
water (1000 ml). The ether layer was separated and washed with a
further portion of water (1000 ml), sodium sulfite solution (500
ml), sodium hydrogen carbonate solution (3.times.500 ml), brine,
dried over MgSO.sub.4, filtered and evaporated in vacuo to give the
sulfonyl chloride as a white foam 65.7 g (>100%). Step 6
##STR37##
[0118] 4-Methoxybenzylamine (35 ml, 263 mmol) was added dropwise
over 10 minutes to a solution of the product of Step 5 (65.7 g, 105
mmol in dichloromethane (500 ml) stirred at 0.degree. C., under
nitrogen. The reaction mixture was warmed to room temperature over
90 minutes, diluted with dichloromethane (500 ml) and acidified
with citric acid solution (500 ml). The dichloromethane layer was
separated and washed with brine, water (700 ml), dried over
MgSO.sub.4, filtered and evaporated in vacuo. Purification by
column chromatography gave the title intermediate as a pale brown
foam (59.3 g, 88% over 4 steps). Step 7 ##STR38##
[0119] Sodium hydride (4.90 g, 127 mmol) was added to a solution of
the product of Step 6 (59.3 g, 82 mmol) dissolved in
dimethylformamide (700 ml). After stirring at room temperature for
10 minutes the reaction mixture was heated to 75.degree. C. After 2
hours the reaction mixture was cooled to room temperature,
acidified with citric acid solution (500 ml) and diluted with ethyl
acetate (800 ml). The ethyl acetate layer was separated, washed
with water (3.times.500 ml), brine, dried over MgSO.sub.4, filtered
and evaporated in vacuo. Purification by column chromatography gave
the cyclised intermediate as white solid (28.7 g, 56%). Step 8
##STR39##
[0120] Lithium bis(trimethylsilyl)amide (1M in THF, 114 ml, 114
mmol) was added dropwise to a solution the product of Step 7 (28.7
g, 45.5 mmol) in tetrahydrofuran (300 ml) stirring at -2.degree. C.
(internal temperature). The reaction mixture was stirred for 1 hour
at 0.degree. C. under nitrogen, then cooled to -78.degree. C. and
treated with ethyl iodide (4.7 ml, 59.2 mmol). The reaction mixture
was stirred at -25.degree. C. for 18 hours then warmed to
-8.degree. C. and then to room temperature over 2 hours. The
reaction was diluted with ethyl acetate (500 ml), water (500 ml)
and acidified with citric acid solution (500 ml). The ethyl acetate
layer separated and the aqueous layer was extracted with ethyl
acetate (3.times.500 ml). The organics combined, washed with brine,
dried over MgSO.sub.4, filtered and evaporated in vacuo.
Purification by column chromatography gave the alkylated
intermediate as a white foam (23.1 g, 77%).
Step 9:
(3S,4aR,6R,8aS)-6-(2,5-difluorophenyl)-3-ethyl-6-{[4-(trifluoromet-
hyl)phenyl]sulfonyl}octahydro-1H-2,1-benzothiazine 2,2-dioxide
[0121] ##STR40##
[0122] A solution of the product of Step 8 (23.1 g) in
dichloromethane (115 ml) was treated with trifluoroacetic acid (60
ml) dropwise over 5 minutes, and stirred at room temperature under
nitrogen for 30 minutes. The reaction mixture was evaporated in
vacuo and purified by column chromatography gave the title product
as white foam (17 g, 90%, 98.5% ee).
[0123] The white foam (17 g, 98.5% ee) was dissolved in ethyl
acetate (34 ml) and heated to 70.degree. C. Heptane (136 ml) was
added portionwise to the stirred solution under nitrogen. After 2
hours the reaction solution was seeded with a homochiral sample of
the title compound and allowed to stir for a further 1 hour and
then cooled to room temperature. The resulting white solid was
collected by filtration (12 g, 99.5% ee).
[0124] .sup.1H NMR .delta. (ppm)(CDCl.sub.3): 7.67 (2 H, d, J=8.3
Hz), 7.56 (2 H, s), 7.11-7.07 (1 H, m), 6.98-6.83 (2 H, m),
4.71-4.58 (1 H, m), 3.68 (1 H, s), 3.12 (1 H, q, J=9.8 Hz), 2.73 (1
H, t, J=13.5 Hz), 2.54-2.40 (3 H, m), 2.17-1.91 (4 H, m), 1.65-1.48
(3 H, m), 1.14 (3 H, t, J=7.5 Hz).
* * * * *